The role of allergen challenge chambers in the evaluation of anti‐allergic medication: an international consensus paper

Summary Allergic rhinitis (AR) is a common condition with quality of life and economic implications for those affected. Numerous studies have attempted to evaluate treatments for rhinitis, seeking clinically meaningful efficacy and safety results to enable evidence-based treatment decisions. Traditional studies of medications for AR are hampered by many confounding environmental factors as well as suboptimal medication compliance. They are also an unsuitable setting for determination of precise pharmacodynamic properties of medications, including onset and duration of action. Allergen challenge chambers (ACCs) were developed to provide predetermined, controlled allergen levels and to limit variables inherent in traditional studies. An ACC hosts a number of allergen-sensitive subjects who may receive either medication or placebo in a closed environment regulated for temperature, humidity and other variables. Subjects' allergic responses are monitored using subjective and objective assessments throughout the study, and the resultant information contributes significantly to the clinical profile of a medication. This consensus paper provides an in-depth review of the role of ACCs as a means to evaluate treatments in AR, and concludes that ACC trials fulfil an important supportive role in the assessment of anti-allergic medication.

[1]  J. H. Day,et al.  Experimental models for the evaluation of treatment of allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2]  J. H. Day,et al.  Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. , 2005, Allergy and asthma proceedings.

[3]  F. Horak,et al.  Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. , 2005, British journal of clinical pharmacology.

[4]  W. Henderson,et al.  The role of leukotrienes in allergic rhinitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  G. Passalacqua,et al.  Post‐marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  N. Krug,et al.  Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit , 2005, Allergy.

[7]  M. Andersson,et al.  Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. , 2005, The Journal of allergy and clinical immunology.

[8]  A. Day,et al.  Factors affecting the allergic response to ragweed allergen challenge , 2005 .

[9]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis * , 2005, Allergy.

[10]  Martinus Løvik,et al.  The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  I. Vukušič,et al.  Variation in ragweed (Ambrosia artemisiifolia L.) pollen concentration in central Croatia, 2002-2003. , 2004, Annals of agricultural and environmental medicine : AAEM.

[12]  I. Finegold Immunotherapy in the age of anti-IgE , 2004, Clinical reviews in allergy & immunology.

[13]  S. Burastero,et al.  Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. , 2004, The Journal of allergy and clinical immunology.

[14]  R. Berkowitz,et al.  Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. , 2004, Allergy and asthma proceedings.

[15]  J. Bousquet,et al.  The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine , 2004, Allergy.

[16]  F. Horak,et al.  A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC) , 2004, Current medical research and opinion.

[17]  K. Hörmann,et al.  Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. , 2004, The Journal of allergy and clinical immunology.

[18]  C. Pashos,et al.  Economic impact and quality-of-life burden of allergic rhinitis , 2004, Current medical research and opinion.

[19]  E. Levetin,et al.  Correlation of environmental factors with asthma and rhinitis symptoms in Tulsa, OK. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  W. Greisner Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. , 2004, Allergy and asthma proceedings.

[21]  Y. Lau,et al.  Increasing prevalence of allergic rhinitis but not asthma among children in Hong Kong from 1995 to 2001 (Phase 3 International Study of Asthma and Allergies in Childhood) , 2004, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[22]  J. H. Day,et al.  Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU) , 2004, International journal of clinical practice.

[23]  H. Malling,et al.  Clinical efficacy of sublingual and subcutaneous birch pollen allergen‐specific immunotherapy: a randomized, placebo‐controlled, double‐blind, double‐dummy study , 2004, Allergy.

[24]  Soo Cheng,et al.  Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC) , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  N. Krug,et al.  Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  D. Bernstein,et al.  Key pollen allergens in North America. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[27]  R. Puy,et al.  Allergen immunotherapy for asthma. , 2003, The Cochrane database of systematic reviews.

[28]  R. Kane,et al.  A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[29]  S. Spector,et al.  Symptom severity assessment of allergic rhinitis: part 1. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  W. Berger Overview of allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  A. Harris,et al.  Comparison of the effects of desloratadine 5‐mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure , 2003, Allergy.

[32]  J. Bousquet,et al.  Requirements for medications commonly used in the treatment of allergic rhinitis , 2003, Allergy.

[33]  F. Horak,et al.  Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure Trials , 2002 .

[34]  Robert Kane,et al.  Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[35]  T. Yagami Allergies to Cross-Reactive Plant Proteins , 2002, International Archives of Allergy and Immunology.

[36]  J. Weiler,et al.  Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[37]  A. Harris,et al.  Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. , 2002, The Journal of allergy and clinical immunology.

[38]  S. Willsie Improved strategies and new treatment options for allergic rhinitis , 2002, The Journal of the American Osteopathic Association.

[39]  K. Baba,et al.  [Clinical efficacy of Ebastine under placebo-controlled outdoors clinical study on cedar pollinosis]. , 2002, Arerugi = [Allergy].

[40]  R. Leurs,et al.  H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  Erkka Valovirta,et al.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). , 2002, The Journal of allergy and clinical immunology.

[42]  J. A. Grant,et al.  A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[43]  B. Kramer,et al.  Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[44]  R. Naclerio,et al.  Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. , 2001, Archives of internal medicine.

[45]  F. Horak,et al.  Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-release Pseudoephedrine versus Xylometazolin Nasal Spray in Nasal Congestion , 2001, Arzneimittelforschung.

[46]  J. Bousquet,et al.  A revised nomenclature for allergy: An EAACI position statement from the EAACI nomenclature task force , 2001, Allergy.

[47]  F. Horak,et al.  Controlled Comparison of the Efficacy and Safety of Cetirizine 10 mg o.d. and Fexofenadine 120 mg o.d. in Reducing Symptoms of Seasonal Allergic Rhinitis , 2001, International Archives of Allergy and Immunology.

[48]  A. Ellis,et al.  Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[49]  M. Laaidi Forecasting the start of the pollen season of Poaceæ: evaluation of some methods based on meteorological factors , 2001, International journal of biometeorology.

[50]  F. Horak,et al.  Efficacy and Tolerability of Intranasally Applied Dimetindene Maleate Solution versus Placebo in the Treatment of Seasonal Allergic Rhinitis , 2000, Arzneimittelforschung.

[51]  E. Juniper,et al.  Quality of life in patients with allergic rhinitis. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[52]  H. Burge,et al.  Outdoor allergens. , 2000, Environmental health perspectives.

[53]  A. Coste [ENT diseases associated with allergic rhinitis: a review of the literature]. , 2000, Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris.

[54]  D. Frenz Interpreting atmospheric pollen counts for use in clinical allergy: spatial variability. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[55]  J. Weiler,et al.  Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[56]  A. Ellis,et al.  Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. , 2000, The Journal of allergy and clinical immunology.

[57]  C. Bachert,et al.  Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. , 2000, Rhinology.

[58]  G. Passalacqua,et al.  Post‐marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients , 1999, Allergy.

[59]  E Lesaffre,et al.  A note on the number needed to treat. , 1999, Controlled clinical trials.

[60]  J. H. Day,et al.  Environmental exposure unit: a system to test anti-allergic treatment. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[61]  A. Ellis,et al.  Impact on quality of life during an allergen challenge research trial. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[62]  Howarth Assessment of antihistamine efficacy and potency , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[63]  R. Settipane Complications of allergic rhinitis. , 1999, Allergy and asthma proceedings.

[64]  A. Harris,et al.  Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. , 1999, Allergy and asthma proceedings.

[65]  J. Bousquet Rapid symptom relief in rhinitis , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[66]  F. Horak,et al.  Environmental priming influences allergen‐specific nasal reactivity , 1998, Allergy.

[67]  I. Farooqi,et al.  Early childhood infection and atopic disorder , 1998, Thorax.

[68]  N. Jones,et al.  The prevalence of allergic rhinosinusitis: a review , 1998, The Journal of Laryngology & Otology.

[69]  S. Fineman,et al.  Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[70]  S. Spector,et al.  Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[71]  F. Horak,et al.  Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained‐release pseudoephedrine in the management of nasal congestion , 1998, Allergy.

[72]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[73]  S. Bonini,et al.  Pollen‐related allergy in Europe * , 1998, Allergy.

[74]  M. Briscoe,et al.  Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. , 1998, The Journal of allergy and clinical immunology.

[75]  F. Horak,et al.  Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. , 1998, Journal of investigational allergology & clinical immunology.

[76]  F. Horak,et al.  Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study. , 1998, Arzneimittel-Forschung.

[77]  G. Canonica,et al.  Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge , 1998, International Archives of Allergy and Immunology.

[78]  S. Jäger,et al.  Effect of continuous allergen challenge on clinical symptoms and mediator release in dust‐mite‐allergic patients , 1998, Allergy.

[79]  J. H. Day,et al.  Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[80]  M. Trakultivakorn,et al.  Skin prick reaction and nasal provocation response in diagnosis of nasal allergy to the house dust mite. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[81]  J. H. Day,et al.  Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[82]  S. Rønborg,et al.  Exposure chamber for allergen challenge. A placebo‐controlled, double‐blind trial in house‐dust‐mite asthma , 1997, Allergy.

[83]  E. Monroe,et al.  Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. , 1997, The Journal of allergy and clinical immunology.

[84]  G. Canonica,et al.  Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. , 1996, The Journal of allergy and clinical immunology.

[85]  L. Reece,et al.  Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[86]  S. Jäger,et al.  Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. , 1996, Arzneimittel-Forschung.

[87]  R. Nathan Changing strategies in the treatment of allergic rhinitis. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[88]  F Horak,et al.  Quantification of conjunctival vascular reaction by digital imaging. , 1996, The Journal of allergy and clinical immunology.

[89]  F. Horak,et al.  Efficacy of intranasally applied dimethindene maleate solution as spray in adult volunteers with symptoms of seasonal allergic rhinitis in the Vienna challenge chamber. , 1996, Arzneimittel-Forschung.

[90]  J. H. Day,et al.  Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[91]  J. H. Day,et al.  A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[92]  T. Casale,et al.  Speed of onset of action of Tilarin , 1996, Allergy.

[93]  S. Rønborg,et al.  Exposure chamber for allergen challenge The development and validation of a new concept , 1996, Allergy.

[94]  J. Weiler,et al.  Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[95]  L. Reece,et al.  Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. , 1995, American journal of respiratory and critical care medicine.

[96]  T. Casale,et al.  The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. , 1995, American journal of respiratory and critical care medicine.

[97]  L. Juhlin A comparison of the pharmacodynamics of H1‐receptor antagonists as assessed by the induced wheal‐and‐flare model , 1995, Allergy.

[98]  G. Canonica,et al.  Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. , 1995, The Journal of allergy and clinical immunology.

[99]  C. Bindslev‐Jensen,et al.  Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action , 1994, Allergy.

[100]  F. Horak,et al.  Controlled exposure to mite allergen for a dose-finding of dimethindene maleate (DMM) , 1994, Agents and Actions.

[101]  C. Sherbourne,et al.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. , 1994 .

[102]  F. Horak,et al.  Pharmacodynamic dose finding of dimetindene in a sustained release formulation. , 1993, Arzneimittel-Forschung.

[103]  A. Pécoud,et al.  Facial thermography during nasal provocation tests with histamine and allergen , 1993, Allergy.

[104]  S. Jäger,et al.  Effects of H1‐receptor antagonists on nasal obstruction in atopic patients , 1993, Allergy.

[105]  S. Holgate,et al.  The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. , 1993, The Journal of allergy and clinical immunology.

[106]  T. Casale,et al.  Nedocromil sodium is rapidly effective in the therapy of seasonal allergic rhinitis. , 1993, The Journal of allergy and clinical immunology.

[107]  R. Einarsson,et al.  Mite (Der p 1, Der f 1) and cat (Fel d 1) allergens in the homes of babies with a family history of allergy , 1993, Allergy.

[108]  S. Spector The placebo effect is nothing to sneeze at. , 1992, The Journal of allergy and clinical immunology.

[109]  F. Horak,et al.  Onset and Duration of the Effects of Three Antihistamines in Current Use – Astemizole, Loratadine and Terfenadine Forte – Studied during Prolonged, Controlled Allergen Challenges in Volunteers , 1992, The Journal of international medical research.

[110]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[111]  H. Pross,et al.  Immunologic studies of subjects with asthma exposed to formaldehyde and urea-formaldehyde foam insulation (UFFI) off products. , 1987, The Journal of allergy and clinical immunology.

[112]  M. Chapman,et al.  Seasonal variation in dust mite and grass-pollen allergens in dust from the houses of patients with asthma. , 1987, The Journal of allergy and clinical immunology.

[113]  H. Burge,et al.  Allergen carriage by atmospheric aerosol. II. Ragweed-pollen determinants in submicronic atmospheric fractions. , 1984, The Journal of allergy and clinical immunology.

[114]  E. Levetin,et al.  Weather patterns and ragweed pollen production in Tulsa, Oklahoma. , 1982, Annals of allergy.

[115]  Connell Jt A novel method to assess antihistamine and decongestant efficacy. , 1979 .

[116]  S. Freedman,et al.  Double‐blind trial comparing flunisolide and placebo for the treatment of perennial rhinitis , 1978, Clinical allergy.

[117]  E. Arnáiz,et al.  Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[118]  B. Samoliński,et al.  Correlation between conjunctival provocation test results and conjunctival symptoms in pollinosis - preliminary report. , 2005, Annals of agricultural and environmental medicine : AAEM.

[119]  F. Horak,et al.  Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-Release Pseudoephedrine versus Budesonide Nasal Spray in the Management of Nasal Congestion in Allergic Rhinitis , 2005, Treatments in respiratory medicine.

[120]  J. H. Day,et al.  Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. , 2004, Allergy and asthma proceedings.

[121]  C. Naspitz,et al.  Nasal provocation test (NPT) with isolated and associated dermatophagoides pteronyssinus (Dp) and endotoxin lipopolysaccharide (LPS) in children with allergic rhinitis (AR) and nonallergic controls. , 2004, Journal of investigational allergology & clinical immunology.

[122]  J. Weiler,et al.  Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[123]  F. Horak,et al.  Efficacy and Safety of Ketotifen Eye Drops as Adjunctive Therapy to Mometasone Nasal Spray in Subjects with Seasonal Allergic Rhinoconjunctivitis , 2003, Clinical drug investigation.

[124]  S. Weinstein Combination therapy in the treatment of allergic rhinitis. , 2002, Allergy and asthma proceedings.

[125]  C. Arendt,et al.  Efficacy and safety of levocetirizine in seasonal allergic rhinitis. , 2001, Acta oto-rhino-laryngologica Belgica.

[126]  D. Nash,et al.  Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. , 2000, The American journal of managed care.

[127]  J. Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[128]  F. Horak,et al.  Dose-related control of allergic rhinitis symptoms by a H1-receptor antagonist. Finding the proper doses [correction of dosis] of dimethindene maleate in patients with allergic rhinitis. , 1994, International archives of allergy and immunology.

[129]  T Shida,et al.  Measurement of allergens associated with dust mite allergy. II. Concentrations of airborne mite allergens (Der I and Der II) in the house. , 1989, International archives of allergy and applied immunology.

[130]  G. Guyatt,et al.  A comparison of Likert and visual analogue scales for measuring change in function. , 1987, Journal of chronic diseases.

[131]  J. T. Connell A novel method to assess antihistamine and decongestant efficacy. , 1979, Annals of allergy.

[132]  J. T. Connell Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. , 1969, The Journal of allergy.